Skip to main content
. 2024 Nov 8;13(21):e70319. doi: 10.1002/cam4.70319

TABLE 1.

Patients' general characteristics.

Variables Mean/number SD Range/percentage
Patients' general characteristics
Total number 319
Age 70.1 9.1 43–97 year‐old
Height 163.8 6.0 165–179.9 cm
Weight 66.8 10.8 43.1–155.3 kg
BMI 24.9 3.6 17.1–56.6 kg/cm2
Prostate volume
Total 49.1 28.6 3.3–183 gm
T‐zone 20.7 15.8 0.6–72.4
Cancer related parameters
iPSA 629.5 1834.6 2.6–23125.5 ng/mL
ISUP group
1 15 5.1%
2 18 6.1%
3 27 9.1%
4 66 22.3%
5 170 57.4%
DeNovo distant mets
0 65 20.4%
1 254 79.6%
ADT agent
Degarelix 49 15.4%
Goserelin acetate 78 24.5%
Leuprorelin acetate 160 50.2%
Triptorelin 1 0.3%
Orchiectomy 29 9.1%
1st ARAT agent
Abiraterone acetate 177 55.5%
Enzalutamide 142 44.5%
Pre‐ or post‐ Chemo setting
Pre‐chemo 67 21.0%
Post‐chemo 85 26.6%
No chemo 167 52.4%
Nadir PSA during ADT 13.74 45.7 0–354.1 ng/mL
PSA when strating ARAT 214.05 606.9 0.008–5285.2 ng/mL
Follow‐up 79.53 50.6 11.7–247.2 months

Abbreviations: ADT = androgen deprivation therapy; ARAT = androgen receptor‐axis‐targeted therapies; BMI = Body Mass Index; ISUP = International Society of Urological Pathology; PSA = prostate‐specific antigen.